The Infinity DBS system connects to an iPad mini via Bluetooth, through which providers can program patients' therapy and monitor clinical outcomes via Abbott's software platform. Meanwhile, patients can manage their symptoms through an iPod touch-powered controller for the device.
The FDA's expanded clearance of Abbott's DBS system could help Abbott broaden its portfolio of devices targeting neurological conditions. And the new indication could make Abbott's DBS system more appealing and potentially effective for PD patients who are interested in treating themselves with a familiar, patient-friendly device — a trend that has recently And Abbott's DBS system opens the door for providers to tailor treatments to PD patients' unique needs.
The new FDA clearance could give Abbott a competitive edge in the connected device space — and highlights a larger trend of medical device giants embracing connected devices. its own connected DBS device in October 2019, the expanded FDA clearance makes Abbott's DBS system the only directional system approved for all major targets used in the treatment of movement disorders, Parkinson's, and essential tremor.